Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/100.5glegtPn.js ...

The deal will give Zimmer Biomet access to Paragon's surgical implants and equipment used to treat foot and ankle ailments, ...

Paragon 28, Inc. (NYSE:FNA – Get Free Report) has earned a consensus rating of “Hold” from the six ratings firms that are presently covering the company, Ratings reports. Four research analysts have ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $13.4, a ...

Paragon 28, Inc. (NYSE:FNA) shares are trading higher premarket on Wednesday. On Tuesday, the company inked a deal to be ...

Fintel reports that on January 29, 2025, Needham downgraded their outlook for Paragon 28 (NYSE:FNA) from Buy to Hold. Analyst ...

Fintel reports that on January 30, 2025, Stephens & Co. downgraded their outlook for Paragon 28 (NYSE:FNA) from Overweight to ...

Zimmer Biomet made a major play in the foot and ankle treatment space today, announcing it will spend $1.2 billion to acquire ...

Paragon 28 (FNA – Research Report) received a Hold rating and price target from Needham analyst Michael Matson today. The company’s shares ...

Zimmer Biomet Holdings Inc. (ZBH) agreed to acquire all outstanding shares of common stock of Paragon 28 Inc. (FNA) for an upfront ...

Zimmer Biomet is taking steps to expand its foot and ankle orthopedics business with a $1.1 billion deal to acquire ...